Synergistic induction of interferon α through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton rats

Vaccine

Volumn 32, Issue 2, 2014, Pages 265-270

  Kim, Dhohyung ^a   Niewiesk, Stefan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cotton rat; Maternal antibodies; Measles vaccine; Neonatal immunization; Neutralizing antibodies; TLR agonists

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MATERNAL ANTIBODY; MEASLES VACCINE; MESSENGER RNA; NEUTRALIZING ANTIBODY; ODN 2216; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; COTTON RAT; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MEASLES VACCINATION; MEASLES VIRUS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

COTTON RAT; MATERNAL ANTIBODIES; MEASLES VACCINE; NEONATAL IMMUNIZATION; NEUTRALIZING ANTIBODIES; TLR AGONISTS;

ADULT; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INTERFERON-ALPHA; INTERLEUKIN-10; MEASLES; MEASLES VACCINE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; SIGMODONTINAE; SPLEEN; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 84890561333     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.013     Document Type: Article

References (39)

1. Kim D., Niewiesk S. Synergistic induction of interferon alpha through TLR-3 and TLR-9 agonists identifies CD21 as interferon alpha receptor for the B cell response. PLoS Pathog 2013, 9:e1003233.
2. Naniche D. Human immunology of measles virus infection. Measles-pathogenesis and control 2009, 151-171. Springer Verlag, Heidelberg. D.E. Griffin, M.B.A. Oldstone (Eds.).
3. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280:527-532.
4. Gans H.A., Maldonado Y., Yasukawa L.L., Beeler J., Audet S., et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999, 162:5569-5575.
5. Gans H., Yasukawa L., Rinki M., DeHovitz R., Forghani B., et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001, 184:817-826.
6. Gans H., DeHovitz R., Forghani B., Beeler J., Maldonado Y., et al. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003, 21:3398-3405.
7. Siegrist C-A., Barrios C., Martinez X., Brandt C., Berney M., et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 1998, 28:4138-4148.
8. Pueschel K., Tietz A., Carsillo M., Steward M., Niewiesk S. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J Virol 2007, 81:8571-8578.
9. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
10. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
11. Randolph D. The neonatal adaptive immune system. NeoReviews 2005, 6:e454-e462.
12. Green M.G., Huey D., Niewiesk S. The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens. Lab Anim (NY) 2013, 42:170-176.
13. Pfeuffer J., Püschel K., ter Meulen V., Schneider-Schaulies J., Niewiesk S. Extent of measles virus spread and immune suppression differentiates between wildtype and vaccine strains in the cotton rat model (Sigmodon hispidus). J Virol 2003, 77:150-158.
14. Parrula C., Zimmerman B., Nadella P., Shu S., Rosol T., et al. Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia. Vet Pathol 2009, 46:1003-1014.
15. Kim D., Martinez-Sobrido L., Choi C., Petroff N., Garcia-Sastre A., et al. Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies. J Virol 2011, 85:200-207.
16. Weidinger G., Ohlmann M., Schlereth B., Sutter G., Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 2001, 19:2764-2768.
17. Niewiesk S., Götzelmann M., Ter Meulen V. Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection. Proc Natl Acad Sci USA 2000, 97:4251-4255.
18. Schlereth B., Germann P-G., ter Meulen V., Niewiesk S. DNA vaccination with the hemagglutinin and the fusion proteins, but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol 2000, 81:1321-1325.
19. Griffin D.E. Immune responses during measles virus infection. Measles virus 1995, 117-134. Springer, Berlin. M. Billeter, V. ter Meulen (Eds.).
20. Gans H.A., Yasukawa L.L., Alderson A., Rinki M., Dehovitz R., et al. T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunol 2004, 17:298-307.
21. Kumar M.L., Johnson C.E., Chui L.W., Whitwell J.K., Staehle B., et al. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine 1998, 16:2047-2051.
22. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., et al. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196:1339-1345.
23. De Wit D., Tonon S., Olislagers V., Goriely S., Boutriaux M., et al. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun 2003, 21:277-281.
24. De Wit D., Olislagers V., Goriely S., Vermeulen F., Wagner H., et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004, 103:1030-1032.
25. Vosters O., Lombard C., Andre F., Sana G., Sokal E.M., et al. The interferon-alpha and interleukin-10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life. Clin Exp Immunol 2010, 162:494-499.
26. Gold M.C., Donnelly E., Cook M.S., Leclair C.M., Lewinsohn D.A. Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res 2006, 60:34-37.
27. Nguyen M., Leuridan E., Zhang T., De Wit D., Willems F., et al. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLos One 2010, 5:e10407.
28. Krumbiegel D., Zepp F., Meyer C.U. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol 2007, 68:813-822.
29. Bjarnarson S.P., Adarna B.C., Benonisson H., Del Giudice G., Jonsdottir I. The adjuvant LT-K63 can restore delayed maturation of follicular dendritic cells and poor persistence of both protein- and polysaccharide-specific antibody-secreting cells in neonatal mice. J Immunol 2012, 189:1265-1273.
30. Pihlgren M., Tougne C., Schallert N., Bozzotti P., Lambert P.H., et al. CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice. Vaccine 2003, 21:2492-2499.
31. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Siegrist C.A., Davis H.L. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 2001, 30:241-247.
32. Chelvarajan R.L., Raithatha R., Venkataraman C., Kaul R., Han S.S., et al. CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficoll. Eur J Immunol 1999, 29:2808-2818.
33. Wong D.T., Ogra P.L. Neonatal respiratory syncytial virus infection: role of transplacentally and breast milk-acquired antibodies. J Virol 1986, 57:1203-1206.
34. Svet-Moldavsky G.J., Svet-Moldasky I.A. Sarcomas in cotton rats inoculated with Rous virus. Science 1964, 143:54-55.
35. Prince G.A., Jenson A.R., Horswood R.L., Camargo E. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978, 93:771-792.
36. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
37. Trevani A.S., Chorny A., Salamone G., Vermeulen M., Gamberale R., et al. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 2003, 33:3164-3174.
38. Schlereth B., Rose K.J., Buonocore L., ter Meulen V., Niewiesk S. Successful vaccine-induced seroconversion by single dose immunization in the presence of measles virus specific maternal antibodies. J Virol 2000, 74:4652-4657.
39. Schlereth B., Buonocore L., Tietz A., ter Meulen V., Rose J.K., et al. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 2003, 84:2145-2151.